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ABSTRACT
Objective: It is known that local or systemic injection of hemostatic drugs is used to reduce blood loss and number of blood transfusions in patients 
with hypocoagulation and hemorrhagic diathesis. However, the analysis of literature data shows that the drugs applied for the control of bleeding, 
traditionally used in medical practice, are not effective enough. This study deals with the systemic hemostatic activity of bis (2-aminoethan-1-
sulfonate) calcium in the experiment.
Methods: Experimental work in vitro is performed on the blood of healthy male donors, under conditions in vivo it is done on intraperitoneal injection 
in male rats. Thromboelastography was carried out with apparatus Thromboelastography (TEG) 5000 (Haemoscope Corporation, United States). 
The influence of first synthesized derivative and ethamsylate on functional activity of platelets was studied using a platelet aggregation analyzer 
“Biola 230LA” (Russia). Experimental evaluation of the system specific hemostatic activity in vivo was carried out using the model of parenchymatous 
bleeding in mature male rats. The interference came amid registration of bleeding stop time and extent of blood loss.
Results: Bis (2-aminoethan-1-sulfonate) calcium shows procoagulation and proaggregant activity both in vitro and in vivo. Proaggregatory effect of 
bis (2-aminoethan-1-sulfonate) calcium is successfully implemented in the systemic hemostatic activity in terms of parenchymal bleeding, surpassing 
the control group and the group of etamsylate.
Conclusion: The results of these studies reveal potentially high systemic hemostatic activity of bis (2-aminoethan-1-sulfonate) calcium, urging the 
need for further study on this compound and its analogs to create on their basis highly efficient, selective correctors of the hemostatic system.
Keywords: Taurate of calcium, Hemostasis system, Proaggregatory activity, Hemostatic activity.
INTRODUCTION
It is known that local or systemic injection of hemostatic drugs is used 
to reduce blood loss and number of blood transfusions in patients with 
hypocoagulation and hemorrhagic diathesis. Examples include products 
based on fibrin or thrombin for local hemostasis in abdominal surgery 
or traumatology [1], proton-pump inhibitors to prevent recurrence of 
bleeding from the gastrointestinal tract [2], antifibrinolytic funds, and 
desmopressin for the system hemostasis [3]. However, drugs to stop 
bleeding, traditionally used in medical practice, are not always effective 
to lead to the effective reduction of blood loss which is dangerous due 
to the development of hemorrhagic shock, dilutional coagulopathy, or 
thrombosis and thromboembolic complications [4]. Overview of clinical 
recommendations shows that among synthetic systemic hemostatic 
drugs, the highly proved efficacy was confirmed only for tranexamic 
acid, aminocaproic acid, and etamsylate [5,6]. The results of the previous 
research show potentially high activity of some newly synthesized 
compounds relating to hemostasis system in vitro and in vivo [7]. This 
study deals with the systemic hemostatic activity of bis (2-aminoethan-1-
sulfonate) calcium (compound I) (Fig. 1) in the experiment [8].
MATERIALS AND METHODS
Design
All researches are conducted in the following stages [9]:
1.	 The	first	stage	examined	the	impact	of	compound	I	on	the	hemostasis	
system in vitro.
2. The second stage assessed the effect of compound I on hemostasis 
system in vivo after intraperitoneal injection to rats.
3. The third stage studied systemic hemostatic activity of compound I 
under model bleeding conditions following intraperitoneal injection 
to rats.
Under in vitro conditions, the study of the effect on the functional 
activity of platelets was carried out within concentration of 5×10−4–
2×10−3	 mol/l, coagulation hemostasis component - 10−3–10−5	 g/l. 
Under in vivo conditions, rats were intraperitoneally injected with the 
test substances in equimolar concentration which for etamsylate was 
38.1 mg/kg, for the compound I was 73.8 mg/kg.
Experimental work in vitro was performed on the blood of 65 male 
donors. The average age of donors was 20.4±2.2 years old. Informed 
consent for participation in the study was obtained from all 
participants before blood sampling. The study was approved by the 
Ethics Committee of the Bashkirian State Medical University (No. 1 
dated January 2, 2018).
Experimental studies in vivo were performed in vivo on 70 laboratory 
rats in compliance with national legislation and International 
recommendations of the European Convention for the protection of 
vertebrate animals for experimental animals, regulations for laboratory 
practice in preclinical studies. The animals were kept in standard 
conditions of animal quarters with natural lighting, air temperature 
of 20±2°C, and humidity of 55–60% in plastic cages. 24 h before the 
research, the feeding was stopped without limiting the access to water.
Blood sampling from donor volunteers was carried out from cubital 
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vein using the systems of vacuum blood sampling BD Vacutainer® 
(Dickinson and Company, United States). The stage of working with 
laboratory animals included their anesthesia with diethyl ether and 
blood sampling from the jugular vein. Venous blood was stabilized by 
3.8% sodium citrate solution in a ratio of 9:1.
Research on influence of compound I and comparators on platelets 
aggregation was carried out with a laser analyzer of platelet aggregation 
“Biola 230LA” (“Biola,” Russia). For aggregation inductor was used adenosine 
diphosphate	(ADP)	with	a	concentration	of	20	μg/ml	and	collagen	-	5	mg/ml	
produced by “Technology Standard” (city of Barnaul, Russia).
A study of the influence of compound I and comparator on coagulation 
component of hemostasis was conducted by widely accepted clotting 
tests on hemocoagulometer Solar CGL 2110 (“SOLAR,” Belarus). The 
research included the indicators of activated partial thromboplastin 
time, thrombin time, prothrombin time, and fibrinogen concentration 
[10]. The research applied reagents produced by “Technology Standard” 
(Barnaul, Russia).
Thromboelastography was carried out with TEG 5000 device 
(Haemoscope Corporation, United States). The analysis of the 
thromboelastograms defined general tendency of coagulation (R), 
functional activity of platelets and fibrinogen (MA, Angle), activity 
of fibrinolysis (clot lysis time [CLT]), and the physicomechanical 
properties of the formed clots (G). For TEG activator was used 0.2 mol 
CaCl2 (“Technology Standard,” Russia).
The experimental evaluation of the specific systemic hemostatic activity 
in vivo was carried out on viripotent male rats weighing 200–220 g. 
The drugs were injected intraperitoneally 1 h before parenhimatosis 
bleeding simulation. Then, under ether anesthesia was performed 
laparotomy, using longitudinal section along the white line of the 
abdomen. Intestines were directed into the wound, limiting them with 
drapes moistened with warm saline, and the anterior surface of the 
liver. With the help of a special device - a plastic limiter with a round 
hole in the center - the overlapped part of the liver was resected with a 
razor blade. The resected segment in a vertical projection had the form 
of a circle or ellipse, its size and shape were constant. Resulting evenly 
the bleeding wound with smooth edges and a uniform curvature had a 
total area of about 1.5 cm2 and a depth of about 0.3 cm. The interference 
came amid registration of bleeding stop time and extent of blood loss. 
The amount of blood loss was determined by the gravimetric method, 
weighing the blood-soaked gauze material on electronic scales [11].
The study of systemic hemostatic agents in experimental hemorrhage 
induced by heparin was carried out by introducing heparin into the tail 
vein of the experimental animal at a dose of 500 ME/kg 30 min before 
the start of the experiment.
The findings are processed using the statistical package Statistica 10.0 
(StatSoft Inc., USA). The normality of the distribution of actual data was 
checked using the criterion of Shapiro-Wilka. The groups were described 
using the median and interquartile interval. Variance analysis was 
performed using the criterion of Kruskal–Wallis test (for independent 
observations) and Friedman (for repeated observations). Critical level of 
p significance for statistical criteria was taken equal to 0.05.
RESULTS
Results of studies in vitro
The findings determined that the compound I shows hemostatic 
properties exceeding level wise the values of etamsylate (Table 1).
MA indicator, which characterizes the functional activity of platelets, in 
the	presence	of	compound	I	has	been	increased	by	24.7%	(p˂0.001)	and	
15.9% (p=0.001) compared to the control and etamsylate, respectively. 
The index R that characterizes the enzymatic portion of coagulation is 
reduced on adding the compound I in 2.7 times (p=0.002) compared 
to control. This leads to a statistically significant increase of the total 
coagulation potential toward hypercoagulation - the TMA indicator 
reduced	 by	 1.8	 times	 (p˂0.001)	 and	 1.5	 times	 (p=0.003)	 and	 TPI	
increased	 by	 34.1%	 (p˂0.001)	 and	 16.7%	 (p=0.001)	 in	 comparison	
with the control and etamsylate. The values of the clot strength increase 
- the E and G indexes increase in the group of compound I by 1.5 times 
compared to the control. Etamsylate had no effect on indicators of the 
clot strength. Indicators that are responsible for fibrinolysis system 
(CLT, CL30, and LY30) remain at the level of the control values.
The findings of the effect of compound I and etamsylate on platelet 
aggregation (Table 2) show that the injection of 2×10−3	 mol/l of 
compound I leads to increased platelet aggregation on average by 5.5% 
relative to the control values for ADP and collagen, which is higher than 
the comparison drug by 45.6% and 39.2%, respectively.
Analysis on “dose-effect” relationship shows that at a concentration 
of 5×10−4	mol/l of compound I the platelet aggregation grows at an 
average by 2.2% for both inductors. This concentration does not enable 
to register proaggregant activity of etamsylate. The results of the 
study showed that pre-incubation of the comparator was followed by 
spontaneous platelet aggregation, characterized by a clear dependence 
of the effect on the concentration. This effect did not show in the study 
of compound I. This allows concluding that, at the moment of induced 
aggregation, the compound I has a more selective effect on activated 
platelets in contrast to the comparator, the main effect of which falls 
on intact platelets, thereby potentially increasing the risk of blood clot 
formation, on the one hand, and remaining ineffective at the moment of 
bleeding, on the other hand.Fig. 1: The structure of compound I
Table 1: The indicators of thromboelastography under the impact of compound I and etamsylate in vitro
Indicator Control Etamsylate Compound I p2
R, m 12.4 (9.8–12.8) 7.9 (7.4–9.8)α 4.3 (3.7–5.2)α 0.002
Angle, deg 42.6 (41.8–45.6) 47.5 (45.8–50.8)β 60.3 (58.7–64.9)β 0.004
MA, mm 55.7 (53.8–57.2) 61.3 (59.4–63.8)α 69.7 (66.2–73.5)β 0.001
TMA, min 34.8 (33.7–36.5) 29.1 (25.8–31.1)β 20.1 (18.7–22.4)β 0.003
G, dine/cm2 6.2 (5.8–6.6) 6.7 (6.1–7.2) 9.3 (8.7–10.5)β 0.001
E, dine/cm2 126.5 (117.8–139.2) 131.4 (128.7–132.4) 147.2 (140.5–150.4)β 0.001
TPI/s 14.7 (13.8–15.6) 16.3 (15.9–18.2)α 18.9 (17.3–20.2)β 0.001
CL30, % 96.4 (92.5–98.3) 95.6 (93.8–97.5) 94.6 (93.8–98.5) 0.4
LY30, % 0.5 (0.3–0.6) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.7
CLT, min 36.8 (34.8–39.6) 35.4 (33.8–36.9) 37.8 (35.4–39.6) 0.6
CI, 0.5 (0.3–1.2) 1.7 (1.5–1.8)β 2.9 (2.6–3.5)β 0.002
αp<0.05; βp<0.001 - etamsylate or compound I versus control; p2 - etamsylate versus compound I. CLT: Clot lysis time
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The findings followed by the impact of hemostasis on the coagulation 
component (Table 3) show that compound I speeds up clot formation in 
the extrinsic coagulation pathway by 21.6% (p=0.001).
There were no registered cases when etamsylate had impact on the 
standard coagulogram rates.
Results of studies in vivo
The next stage examined the impact of compound I and etamsylate 
on functional activity of platelets at intraperitoneal injection into rats 
(Table 4).




(p≤0.001)	 in	 comparison	 with	 the	 etamsylate	 for	 both	 inductors	 of	
aggregation. The average radius of platelet aggregates in the presence 
of compound I and ADP and for collagen is higher than in the control 
group	by	2.3	times	(p≤0.001)	and	in	group	of	etamsylate	-	by	1.6	times	
(p≤0.001).
The findings of systemic hemostatic activity on the model of 
parenhimatosis hemorrhage in rats are presented in Table 5.
Table 5 data show that on intraperitoneal injection into rats the 
etamsylate reduced bleeding time by 26.5% (p=0.002) in comparison 
with the control group without significant impact on the total amount of 
blood loss. Compound I reduces the bleeding time by 34.9% (p=0.0003) 
and 11.5% (p=0.001) compared to the control and etamsylate, 
respectively. This effectively decreased the volume of blood loss by 2.2 
(p=0.0002) and 1.9 (p=0.0001) times in comparison with the control 
group and that of etamsylate, respectively.
Preliminary intravenous injection of heparin in the control group 
resulted	 in	 increased	 bleeding	 time	 and	 blood	 loss	 by	 1.5	 (p≤0.001)	
Table 2: Indicators of ADP- and collagen-induced platelet aggregation under the influence of etamsylate and compound I in vitro
No Sample Concentration, mol/l Spontaneous 
aggregation of platelets 
(% to the control)
Enhancement of ADP-induced 
platelet aggregation 
 (% to the control)
Enhancement of collagen-induced 
platelet aggregation  
(% to the control)
1 Etamsylate 2×10−3 23.2 (20.5–24.6) 3.3 (2.6–4.3) 3.2 (2.4–4.5)
10−3 9.8 (7.2–12.7) 2.2 (1.6–3.3) 2.4 (1.2–2.7)
0.5×10−3 2.7 (1.3–5.4) 0.0 (0.0–0.0) 0.0 (0.0–0.0)


















p - difference in groups etamsylate versus compound I
Table 3: Influence of compound I and etamsylate on coagulogram in vitro
Indicator Control Etamsylate p1 Compound I p2 p3
APTT, s 23.1 (21.6–24.7) 23.4 (22.7–24.8) 0.7 18.1 (17.5–19.3) 0.001 0.002
TT, s 27.2 (26.4–28.9) 28.3 (27.5–29.6) 0.2 26.5 (25.7–28.9) 0.4 0.3
PT, s 12.4 (11.5–13.9) 12.9 (11.5–14.3) 0.3 12.7 (11.8–14.5) 0.5 0.3
Fibrinogen, s 24.3 (22.5–26.7) 25.9 (24.7–26.3) 0.2 24.6 (23.5–25.9) 0.9 0.5
APTT: Activated partial thromboplastin time, TT: Thrombin time, PT: Prothrombin time, p1 - etamsylate versus control, p2 - compound I versus control, p3 - etamsylate 
versus compound I
Table 4: Indicators of ADP- and collagen-induced platelet aggregation in rats following intraperitoneal injection of etamsylate and 
compound I into rats
No Indicator Control Etamsylate Compound I p2
1 Collagen, mm 54.8 (53.6–57.6) 65.8 (63.5–68.7) p1=0.006 77.8 (74.9–79.1) p1=0.002 0.0001
2 MPA (collagen), r.u. 6.4 (6.1–6.9) 9.2 (7.6–10.6) p1=0.001 14.8 (12.7–15.2) p1=0.0001 0.002
3 tg	α.(collagen),	s 36.7 (34.9–39.4) 35.9 (35.6–38.4) p1=0.02 46.9 (45.7–49.8) p1=0.0003 0.0001
4 ADP, mm 53.6 (51.8–58.5) 68.3 (66.2–69.7) p1=0.002 79.4 (75.3–80.1) p1=0.0002 0.0008
5 MPA (ADP), r.u. 6.2 (6.1–7.0) 8.7 (7.3–10.5) p1=0.002 13.8 (11.6–14.7) p1=0.0001 0.001
6 tg	α	(ADP),	s 43.2 (40.6–44.1) 46.8 (45.4–48.3) p1=0.001 57.9 (58.3–59.4) p1=0.0002 0.004
p1 - etamsylate or compound I versus control; p2 - etamsylate versus compound I. r.u.: Relative units
Table 5: Indicators of hemostatic activity of etamsylate and compound I following intraperitoneal injection into rats
Model Indicator Control Etamsylate Compound I
I Bleeding time, s 96.8 (94.3–98.7) 70.4 (70.1–74.6) p1=0.002 63.7 (61.8–66.2) p1=0.0003 p2=0.001
Δ	weight	of	drapes,	g 7.3 (7.1–8.4) 6.7 (5.9–7.3) p1=0.2 3.5 (3.4–4.2) p1=0.0002 p2=0.0001
II Bleeding time, s 137.4* (135.6–143.8) 137.9 (136.2–138.1) p1=0.2 112.4 (110.5–113.8) p1=0.002 p2=0.001
Δ	weight	of	drapes,	g 10.5* (8.7–11.3) 9.9 (8.5–11.1) p1=0.3 6.4 (5.5–7.2) p1=0.001 p2=0.002
*p≤0.05	-	Group	I	model	versus	Group	II	model	for	control.	p1 - etamsylate or compound I versus control; p2 - etamsylate versus compound I. Model: I - intact rats, 
II - model of hypocoagulation induced by heparin injection
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and	1.3	(p≤0.001)	times,	respectively.	There	was	no	record	of	positive	
impact of etamsylate on the reduction of test indicators in a systemic 
hypocoagulation. Compound I reduced the bleeding time and blood loss 
on	average	by	19.5%	(p≤0.001)	and	39.0%	(p≤0.001)	compared	with	
groups control and etamsylate.
DISCUSSION
Etamsylate is a chemically 2,5-dihydroxybenzenesulfonic acid 
with N-ethylethanamine. Molecular formula is C10H17NO5S, and its 
molecular weight is 263.33 g/mol. Etamsylate is completely soluble 
in water, methanol, and ethanol but partially soluble in methylene 
chloride [12].
Etamsylate is long enough used as a means to prevent and treat 
diapedetic hemorrhages, hemoptysis, melena, hematuria, and 
menorrhagia [13,14]. In addition, etamsylate is effective in the 
prevention and treatment of bleeding during operational period 
on interventions in the well-vascularized tissues, in such realms as 
otolaryngology, gynecology, obstetrics, urology, ophthalmology, plastic, 
and reconstructive surgery [6].
The main hemostatic effect of etamsylate is realized due to 
proaggregatory activity and potentiating of platelets adhesion. The 
research made by Sack and Dujovne shows that etamsylate provokes 
aggregation of platelets in platelet-enriched plasma, but such platelet 
aggregation is minor and reversible [15]. The study of biochemical 
prerequisites of proaggregation platelets effect of Okum et al. helped 
to determine that etamsylate enhances platelet aggregation and ATP 
release induced by arachidonic acid, thromboxane A2, collagen, and 
calcium ionophore A23187 but not ADP and/or adrenaline [16].
The own findings established that the main effect of etamsylate falls on 
intact platelets. The gain of adhesive functions of platelets contributes 
to the increased risk of thrombosis, whereas etamsylate remains 
ineffective at the time of bleeding not associated with damage of 
parenchymatous organs [17,18].
The findings of the experimental work proved that the new 
bis(2-aminoethan-1-sulfonate) calcium shows hemostatic activity 
that exceeds the values of etamsylate both in vitro and in vivo. 
The compound I activity data in vivo fully corresponds to the data 
obtained at the stage in vitro. Compound I showed proaggregatory 
activity after intraperitoneal injection in laboratory rats, more 
efficient than etamsylate by reducing the volume of blood loss 
and bleeding time on the models of parenchymal bleeding in the 
standard terms and conditions heparin-induced hypocoagulation. 
It should be noted that at the time of induced platelet aggregation, 
the compound I has a more selective effect on activated platelets, 
increasing the overall hemostatic potential due to the existing 
procoagulation effect, that is, particularly effective under the 
original existing hypocoagulation.
CONCLUSION
The results of the preclinical studies reveal the potentially high systemic 
hemostatic activity of bis(2-aminoethan-1-sulfonate) calcium and urge 
further study of this compound and its analogs to create on their basis 
highly effective systemic hemostatic agents.
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